表阿霉素联合索拉非尼增强乳腺癌MCF-7细胞凋亡体外研究

Co-administration of Sorafenib and Epirubicin enhanced the apoptosis of breast cancer MCF-7 cell in vitro

目的探讨表阿霉素(Epirubicin)联合分子靶向药索拉非尼(Sorafenib)对乳腺癌MCF-7细胞凋亡作用。方法采用人乳腺癌(MCF-7)细胞株。实验分为4组,即对照组、表阿霉素单药组、索拉非尼单药组、索拉非尼+表阿霉素联合组。对各组细胞给予相应药物处理,72h后经流式细胞仪检测各组药物对MCF-7细胞凋亡的作用。结果索拉非尼或表阿霉素单药作用后经流式细胞仪检测,细胞凋亡率均较对照组升高(P<0.05),索拉非尼组诱导的细胞凋亡率为6.34%,表阿霉素组为13.35%。与单药组比,索拉非尼+表阿霉素联合组凋亡率升高更为明显,达23.47%(P<0.05)。结论索拉非尼和表阿霉素的联合应用使抗肿瘤活性显著增强。

Objective To investigate the effect of Sorafenib in combination with Epirubicin（EPI） on the apoptosis of breast cancer MCF-7 cells, Methods Human breast eaneer（MCF-7） cells were divided into four different groups： control group, Sorafenib group, EPI group and Sorafenib ＋ EPI group. The cell apoptosis was detected by flow eytometry via Annexin V-FITC/PI double staining after 72 hours. Results The apoptosis rate of single treated group was higher than that of control group （P 〈 0.05）. Compared with Sorafenib（6.34 %） and Epirubicin（13.35 %） single drug group, the apoptosis rate of Sorofenib ＋ EPI combination group increased more significantly, reached 23.47 %（P 〈 0.05）. Conclusion It is demonstrated that the combined application of Sorafenib and Epirubicin could enhance the anti-tumor activity.